• PHOX2B gene mutation analysis
  • Toxoplasma gondii, Molecular Detection, PCR
  • COL1A1/COL1A2 Genes Variations Analysis
  • Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management
  • Cimetidine, Urine
  • Isoniazid, Serum
  • Cytomegalovirus (CMV) Genotyping and Drug Resistance
  • Aspergillus Antibody, IgE, Serum
  • Aminolevulinic Acid, Urine
  • Halazepam, Urine
  • LDS
  • Sign up
  • Log in
  • LDS
  • /Medical Tests
  • /Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References

Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management
Medical Test

Turnaround Time
Access to Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management is restricted.
Loading...